Tocilizumab-effects on growth impairment in systemic juvenile idiopathic arthritis

被引：0
|
作者：
Takako Miyamae
Tomo Nozawa
Masako Kikuchi
Toshitaka Kizawa
Tomoyuki Imagawa
Shumpei Yokota
机构：
[1] Yokohama City University,Department of Pediatrics
来源：
Pediatric Rheumatology | / 9卷 / Suppl 1期
关键词：
Tocilizumab; Standard Deviation Score; Corticosteroid Dose; Growth Impairment; Systemic Juvenile Idiopathic Arthritis;
D O I：
10.1186/1546-0096-9-S1-P130
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with tocilizumab
    Fabrizio De Benedetti
    Rayfel Schneider
    Sheila Weitzman
    Clare Devlin
    Kaori Daimaru
    Shumpei Yokota
    Syuji Takei
    Angelo Ravelli
    Pediatric Rheumatology, 12 (Suppl 1)
  • [22] Efficacy and safety of tocilizumab in european children with systemic onset juvenile idiopathic arthritis
    O Nemiche
    R Dagner
    P Quartier
    R Cimaz
    O Richer
    P Pillet
    M Hofer
    Pediatric Rheumatology, 9 (Suppl 1)
  • [23] Tocilizumab: A Review of Its Use in the Treatment of Juvenile Idiopathic Arthritis
    James E. Frampton
    Pediatric Drugs, 2013, 15 : 515 - 531
  • [24] Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis
    Masaki Shimizu
    Mao Mizuta
    Nami Okamoto
    Takahiro Yasumi
    Naomi Iwata
    Hiroaki Umebayashi
    Yuka Okura
    Noriko Kinjo
    Tomohiro Kubota
    Yasuo Nakagishi
    Kenichi Nishimura
    Mariko Mohri
    Masato Yashiro
    Junko Yasumura
    Hiroyuki Wakiguchi
    Masaaki Mori
    Pediatric Rheumatology, 18
  • [25] Tocilizumab in Systemic Juvenile Idiopathic Arthritis: Response Differs by Disease Duration at Medication Initiation and by Phenotype of Disease
    Yan, Xin
    Tang, Wenjing
    Zhang, Zhiyong
    Zhang, Yu
    Luo, Chong
    Tang, Xuemei
    FRONTIERS IN PEDIATRICS, 2021, 9
  • [26] Reasons for inactive disease and flare in systemic onset juvenile idiopathic arthritis patients during tocilizumab treatment
    Kostik, M. M.
    Isupova, E. A.
    Chikova, I. A.
    Dubko, M. F.
    Masalova, V. V.
    Snegireva, L. S.
    Kalashnikova, O., V
    Chasnyk, V. G.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (02) : 335 - 341
  • [27] Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis
    Shimizu, Masaki
    Mizuta, Mao
    Okamoto, Nami
    Yasumi, Takahiro
    Iwata, Naomi
    Umebayashi, Hiroaki
    Okura, Yuka
    Kinjo, Noriko
    Kubota, Tomohiro
    Nakagishi, Yasuo
    Nishimura, Kenichi
    Mohri, Mariko
    Yashiro, Masato
    Yasumura, Junko
    Wakiguchi, Hiroyuki
    Mori, Masaaki
    PEDIATRIC RHEUMATOLOGY, 2020, 18 (01)
  • [28] Efficacy and safety of tocilizumab in Chinese patients with systemic juvenile idiopathic arthritis: a multicentre phase IV trial
    Li, Caifeng
    Tang, Xuemei
    Zhou, Zhixuan
    Sun, Li
    Lu, Meiping
    Zhou, Wei
    Yang, Sirui
    Zheng, Wenjie
    Yu, Haiguo
    Tan, Weiping
    Zhang, Junmei
    Zhang, Yu
    Kong, Yuxiu
    Xu, Jiahui
    CLINICAL RHEUMATOLOGY, 2024, 43 (11) : 3457 - 3467
  • [29] Effective therapy of tocilizumab on systemic juvenile idiopathic arthritis-associated refractory macrophage activation syndrome
    Wu, Jianqiang
    Sun, Li
    Tang, Xuemei
    Zheng, Qi
    Guo, Li
    Xu, Li
    Li, Yandie
    Lu, Meiping
    MODERN RHEUMATOLOGY, 2022, 32 (06) : 1114 - 1121
  • [30] Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis under Treatment with Tocilizumab
    Yokota, Shumpei
    Itoh, Yasuhiko
    Morio, Tomohiro
    Sumitomo, Naokata
    Daimaru, Kaori
    Minota, Seiji
    JOURNAL OF RHEUMATOLOGY, 2015, 42 (04) : 712 - 722
12345